DRUG:NASDAQ
Bright Minds Biosciences Inc
$52.03
arrow_upward
+1.42%(+0.73) 1D
Oct 19, 10:52:59 AM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for DRUG...
Open
$53.07
High
$53.07
Low
$49.87
Mkt. cap
720.37M
Avg. vol.
126.02K
Volume
33.48K
52-wk high
$123.75
52-wk low
$47.23
Beta
-5.21
Shares outstanding
9.86M
No. of employees
26
Open
$53.07
High
$53.07
Low
$49.87
Mkt. cap
720.37M
Avg. vol.
126.02K
Volume
33.48K
52-wk high
$123.75
52-wk low
$47.23
Beta
-5.21
Shares outstanding
9.86M
No. of employees
26
News stories
From web sources and news partners
finance.biggo.com
·
38 minutes ago
He makes 3 decisions a year (and beat the S&P 500 for 11 years)｜My First Million
Devdiscourse
·
28 minutes ago
US STOCKS-S&P 500, Nasdaq climb as AI-linked stocks recover ahead of earnings
GuruFocus
·
32 minutes ago
Bank of America Securities Upgrades Dow Inc. (DOW) to Neutral on Rising Chemical Prices
TradingView
·
1 hour ago
The Dow Jones Index Opens 0.08% Lower
Profile
Bright Minds Biosciences is an American pharmaceutical company which is developing serotonin 5-HT₂ receptor agonists for potential medical use.
It has a particular focus on serotonin 5-HT2C receptor agonists, for instance to treat rare epilepsies and other conditions. Another area of focus for the company is serotonergic psychedelics and non-hallucinogenic psychoplastogens.
The company was co-founded by Ian McDonald and Gideon Shapiro. The lead scientist at Bright Minds Biosciences was previously Alan Kozikowski. Bright Mind Biosciences was founded in 2017 and its headquarters are in New York City, New York. Wikipedia
About Bright Minds Biosciences Inc